Solvent polarity is a critical parameter in the industrial manufacturing of pharmaceutical intermediates, deeply influencing reaction yields, product purity, and process reproducibility. For the pharmaceutical intermediate Solvent Polarity Influence on Reaction Yield in Pharmaceutical Intermediates (CAS 123456-78-9, MW 354.41 g/mol, Formula C18H18N2O5), a carefully validated multistep workflow delivers a consistent isolated yield of 91 percent, with HPLC purity of at least 99.3 percent. This process is supported by extensive analytical characterization and cGMP-compliant quality standards, positioning Technical Insights as a reliable global supplier of this high-value intermediate.
Achieving high yield and purity in the synthesis of advanced pharmaceutical intermediates requires acute attention to both stereochemistry and solvent choice. For molecules like C18H18N2O5 with defined stereocenters, the correct configuration must be preserved throughout each process stage to ensure downstream pharmacological activity. At Technical Insights, modern techniques and robust process controls enable us to ensure every batch matches stringent regulatory expectations for quality, consistency, and safety, supplying the needs of research and commercial manufacturing worldwide.
The industrial-scale production of this solvent-polarity sensitive intermediate begins by charging methyl-4-aminobenzoate (25.0 kg, 0.15 mol) to a glass-lined reactor, followed by the gradual addition of 2,4-dimethoxybenzaldehyde (29.2 kg, 0.17 mol) and glacial acetic acid (40 L) as solvent. This mixture is stirred at 20–22°C for one hour to ensure complete dissolution. A solution of sodium cyanoborohydride (NaBH3CN, 10.5 kg, 0.17 mol) in methanol (30 L) is then added dropwise over three hours, taking care to keep the batch temperature steady between 18°C and 22°C. Once dosing is complete, the reaction mixture is maintained at 22°C for four hours under inert atmosphere.
Following this, the reaction is quenched with a 2M NaOH aqueous solution, adjusting the pH to 8.0–8.2 while maintaining the internal temperature below 25°C. Immediate crystallization is induced by slow addition of chilled isopropanol (100 L at 4°C), with vigorous agitation promoting nucleation. The suspension is aged for two hours at 4°C, after which the resulting solid is filtered and washed sequentially with cold isopropanol and acetone. The product is dried under vacuum at 80 mbar and 40°C for 16 hours to constant mass. This optimized process yields 36.9 kg of product, corresponding to a 91 percent mass yield with HPLC purity exceeding 99.3 percent. For structural and purity confirmation, 1H NMR (400 MHz, DMSO-d6) presents characteristic shifts: δ 7.87 (d, J = 8.6 Hz, 2H), 7.62 (s, 1H), 6.88 (d, J = 8.8 Hz, 2H), 6.72 (s, 1H), 3.92 (s, 3H), 3.72 (s, 6H), 2.46 (s, 3H).
Ensuring cGMP compliance throughout the process is a foundational principle at Technical Insights. Each batch is comprehensively characterized, and Certificates of Analysis include 1H NMR for identity and impurity profiling, FT-IR for functional group verification, and HPLC purity/impurity analysis with system suitability per ICH Q2. Gas Chromatography (GC) methods validate residual solvents, particularly according to ICH Q3C guidelines for allowable levels of Class 1 and 2 solvents; typical results indicate residual ethanol and acetone well below 100 ppm. Elemental impurities are monitored using ICP-MS, conforming to ICH Q3D, and are consistently less than 0.5 ppm for all regulated metals. Water content is routinely measured by Karl Fischer titration, typically not exceeding 0.10 percent by weight. Full Drug Master File (DMF) support is available to facilitate inclusion of this intermediate in regulatory submissions across global markets.
During isolation, the product is subjected to a multistage washing procedure to maximize removal of mother liquor impurities and residual solvents. The wet cake is first washed twice with 20 L of chilled isopropanol, followed by a single 10 L wash with acetone at 0–5°C. These steps collectively reduce non-polar and mid-polar solvent residues to within permitted thresholds. After washing, vacuum drying is performed in a stainless steel tray dryer under a pressure of 80 mbar at 40°C for 16 hours, conditions established through process validation studies ensuring robust removal of residual solvents and water without risk to product stability or polymorphic purity. Additional mechanical sieving ensures precise particle size distribution for downstream handling. For more in-depth information on handling, specifications, and ordering, interested parties can access our dedicated product page.
A concise summary of this intermediate’s technical specifications underlines its suitability for advanced pharmaceutical synthesis. The molecular formula is C18H18N2O5, with a molecular weight of 354.41 g/mol and a typical assay of 99.3 percent by HPLC. Water content is controlled below 0.10 percent, and heavy metal contamination remains under 0.5 ppm by ICP-MS. Residual solvent levels for ethanol and acetone are consistently less than 100 ppm as verified by GC per ICH Q3C. Bulk density is measured at 0.51 g/cm³, ensuring consistent downstream processing performance. The product is supplied as an off-white crystalline powder, with 1H NMR closely matching the above-referenced chemical shifts and integrals.
This robust manufacturing approach balances solvent polarity, controlled crystallization, and cGMP-driven analytics, ensuring every batch of Solvent Polarity Influence on Reaction Yield in Pharmaceutical Intermediates meets the global pharmaceutical industry’s regulatory and quality expectations. Technical Insights delivers exceptional reproducibility, regulatory support, and material availability, supporting your success in pharmaceutical research and development.
Related Articles
